AN2 Therapeutics, Inc. (ANTX)

2.3850 +0.0150 (+0.63%) As of 01:22PM EDT. Market open.

AN2 Therapeutics, Inc.

1800 El Camino Real
Suite D
Menlo Park, CA 94027
United States
650 331 9090
https://www.an2therapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 41

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joseph S. Zakrzewski	Co-founder & Chairman of the Board	76.5k	N/A	1962
Mr. Eric E. Easom	Co-founder, CEO, President & Director	920k	N/A	1968
Dr. Paul Eckburg M.D.	Chief Medical Officer	688.2k	N/A	1970
Dr. George Harrison Talbot FACP, M.D.	Co-Founder & Senior Clinical Advisor	N/A	N/A	1948
Dr. Michael R. K. Alley Ph.D.	Co-Founder & Head of Biology	N/A	N/A	N/A
Dr. Sanjay Chanda Ph.D.	Chief Development Officer	N/A	N/A	1965
Mr. Kevin Krause B.S., M.B.A.	Chief Strategy Officer	N/A	N/A	1975
Ms. Jennifer Huber	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Ms. Annie Yoshiyama	VP of Finance & Corporate Controller	N/A	N/A	1984

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Corporate governance

AN2 Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.